Predicting treatment eligibility for hepatitis B in low income regions: Can treatment scores without HBV DNA testing serve the purpose?

Chronic hepatitis B virus (HBV) infection has a major global impact, ranking alongside malaria, tuberculosis and HIV in terms of mortality rates. The World Health Organization (WHO) estimates that 257 million people are living with chronic HBV infection worldwide.1 The prevalence of HBV is highest in the Asian-Pacific Region and in Africa. The major Liver Societies in Europe (the European Association for the Study of the Liver [EASL]), North America (the American Association for the Study of Liver Diseases) and Asia (the Asian Pacific Association for the Study of the Liver) have published evidenced-based guidelines for the care and treatment of patients with chronic HBV infection.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research